abbott see decent result thank nutrit
diagnost freestyl libr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim apr
price data oct
rate updat oct
currenc amount express
methodolog valu compani
abbott report third-quart result held
surpris remain track hit full-year
project top bottom line weve made
materi chang forecast plan rais
fair valu estim modestli reflect cash flow realiz
sinc last updat overal think narrow-moat abbott
execut well new product cycl
meaning innov particular adopt alin
diagnost strength electrophysiolog portfolio
ablat irrig cathet newli approv
freestyl libr sensor last day long-term
concern abbott abil nurtur cultur
innov remain mind
pleas see intern pediatr nutrit
return double-digit organ growth nice
return patienc investor display wait
china work new regulatori framework infant
formula last year one largest
multi-national competitor chines market abbott
resourc compli new govern regul
caus smaller nativ formula produc
leav market
continu success freestyl libr flash also
high point abbott set libr price significantli
lower dexcom medtron guardian cgm
system abbott abl take share
suspect draw type patient away multipl
finger stick day addit weve seen
monitor technolog abbott sensor offer
accuraci earlier sensor expect abbott
maintain pressur user-friendli
price libr rais bar
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
abbott manufactur market medic devic blood glucos
monitor kit nutrit healthcar product diagnost product
equip brand gener drug product includ pacemak
formula nutrit liquid adult vessel closur devic lasik
equip abbott deriv approxim sale outsid unit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
see abbott busi pop year-
over-year growth fourth quarter immedi
follow food drug administr approv
product septemb howev energi
dissip three quarter mute result
follow three quarter
manag sign roughli hospit base onto
risk-bas contract featur antibacteri
tyrx envelop contract cover
cost patient whose devic becom infect
implant tyrx
system surmis proposit take
financi risk costli infect mileston
reach critic mass hospit contract
shield firm full brunt abbott new product
come recent transcathet cardiovascular
therapeut confer surpris coapt
trial result demonstr efficaci mitraclip
patient sever function mitral regurgit
artifact underli heart failur enlarg left
ventricl prospect expand mitraclip
indic beyond degen mitral regurgit
significantli larger pool fmr patient
attract remain somewhat cautiou sever
reason first favor coapt data inconsist
earlier mitra-fr data fail demonstr
benefit month exampl patient outcom
rehospit mortal differ
trial term patient select practition
experi time frame make difficult compar
result nonetheless conflict trial data suggest well
need build studi consensu reach
second clear durabl coapt result
underli heart failur continu progress even
slower rate would seen without mitraclip
pull mitral valv askew three four year
despit current success still hold
question abbott abil consist innov
especi medic devic on-going cultiv
necessari maintain price power
addit seen competitor
move aggress chang basi
competit technolog innov
price entri weve pay particular attent
abbott cardiac rhythm manag segment sinc
launch mri-compat pacemak implant
cardiovert defibril last fall base
histor cycl new product launch would
expect see abbott outpac market growth captur
anywher point market share first
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
